04/30/2026
Today marks a meaningful advancement in neuropsychiatric care.
Axsome Therapeutics announced that the FDA has approved AUVELITY® (dextromethorphan HBr/bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease.
As someone who speaks on behalf of Axsome and has spent much of my career focused on glutamatergic modulation, NMDA receptor activity, and novel mechanisms in psychiatry, this approval is especially significant to me.
Agitation in Alzheimer’s disease is not simply “behavioral difficulty.” It can be one of the most distressing, dangerous, and caregiver-burdening aspects of dementia care. It affects patients, families, long-term care teams, and clinicians who are often left with limited options.
What stands out about this approval is the continued movement toward mechanism-based treatment in brain health. AUVELITY targets NMDA and sigma-1 receptors via its dextromethorphan component, and bupropion increases dextromethorphan exposure by inhibiting CYP2D6. This represents a distinct approach in an area of substantial unmet need.
This is also a reminder that neuroscience is evolving. Psychiatry and neuropsychiatry are no longer limited to older symptom-suppression frameworks alone. We are increasingly seeing treatments developed around circuits, neurotransmitter systems, neuroplasticity, and functional outcomes.
Congratulations to the Axsome team on this important milestone, and more importantly, to the patients, families, caregivers, and clinicians who may now have another FDA-approved option in a very difficult area of care.
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s...